Curis Provides First Quarter 2023 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Related Keywords

United States ,Evelo Biosciences ,Jonathan Zung ,James Dentzer ,Exchange Commission ,Curis Inc ,Drug Administration ,Nasdaq ,Emory University ,Genentech ,Development Officer ,Roche Group ,Pfizer ,Curis Executive Team ,Bristol Myers Squibb ,Prnewswire Curis Inc ,Covance ,Chief Development ,Recent Operational ,Chief Development Officer ,Aim Lymphoma ,Aim Leukemia ,Orphan Drug Designation ,Takeaim Leukemia ,Note Regarding Forward Looking Statements ,Securities Litigation Reform Act ,Takeaim Lymphoma ,Oberland Capital ,Curis ,Nc ,